What did @nataliejillfit actually say?
The core argument here is a three-part story: HRT was wrongly demonized, the FDA has since reversed course, and now a real estrogen patch shortage is leaving menopausal women scrambling. She claims prescriptions are up 86%, the FDA removed the black box warning, and that switching between manufacturers could mean getting "20% less of the actual hormone." She also recommends calling your doctor to double up on lower-dose patches or switch to gels as a workaround.
The tone is frustrated and advocacy-driven, which is understandable. But frustration doesn't exempt any of these claims from scrutiny. Some of what she says is well-supported. Some of it is oversimplified in ways that could matter clinically.
Does the science back this up?
The HRT-was-wrongly-vilified narrative is largely accurate. The 2002 Women's Health Initiative study spooked an entire generation of clinicians and patients, but subsequent reanalysis showed the risks were overstated and heavily age-dependent. Manson et al. (2013, JAMA) found that women who initiated HRT closer to menopause onset saw cardiovascular benefit, not harm. The North American Menopause Society has since updated guidance accordingly.
The estrogen patch shortage is real and documented. The FDA's drug shortage database has listed estradiol patches intermittently since 2022, with manufacturers including Mylan and Noven citing supply chain and manufacturing capacity issues. Women reporting pharmacy runs across multiple locations is consistent with what pharmacists and prescribers have described publicly.
The 86% prescription increase figure is harder to pin down precisely. Some data from IQVIA and Symphony Health suggests HRT prescriptions rose significantly between 2019 and 2023, but "86%" is a specific number that needs a specific source, and she doesn't cite one.
What did they get wrong (or right)?
The FDA black box warning claim needs a correction. The FDA did not fully remove the black box warning from estrogen products. As of 2024, estrogen-containing HRT products still carry a black box warning, though the language has been updated over time. What changed is clinical consensus, not the label itself. Saying the FDA "removed the black box warning" is inaccurate and could give patients a false sense of regulatory clearance that does not currently exist.
The 20% hormone variance between manufacturers is where things get genuinely complicated. FDA bioequivalence standards for transdermal patches require that generic products fall within 80-125% of the reference product's pharmacokinetic parameters. So technically, a generic could deliver somewhat less or more drug than the brand. Whether that translates to a clinically meaningful 20% symptom-level difference depends on the individual. This claim is not fabricated, but it is presented without the context that most patients tolerate generic switches without dramatic symptom changes. Ying et al. (2021, Clinical Pharmacokinetics) found variability in transdermal delivery systems, but concluded most generics met bioequivalence thresholds.
Her workaround advice, specifically doubling up on lower-dose patches, is something she frames as coming from a doctor conversation, which is the right framing. But presenting it as a general strategy on social media, without emphasizing that this must be individualized and physician-guided, is where the line gets blurry. Do not adjust your patch dose without talking to your prescriber.
What should you actually know?
Menopausal hormone therapy is not a monolith. Estradiol patches, gels, sprays, and vaginal preparations have different absorption profiles, different evidence bases, and different risk considerations depending on your personal and family history. The idea that gels and creams are straightforward substitutes for patches is mostly correct for symptom management, but the pharmacokinetics differ enough that some women do not respond identically to both.
If you are affected by the shortage, the right first call is to your prescriber, not a pharmacy. Prescribers can often switch formulations, adjust doses, or identify compounding pharmacies, though compounded estrogen is not equivalent to FDA-approved products and carries its own set of unresolved questions around consistency and safety monitoring. The Menopause Society (formerly NAMS) maintains updated clinical guidance on alternatives during shortage periods.
The Viagra comparison she makes is a rhetorical point, not a clinical one, but it is not wrong as social commentary. Drug shortages affecting men's sexual health have historically received faster regulatory and media attention than those affecting menopausal women. That is a documented pattern worth naming.